Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug Development
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Product Development Partnerships (PDPs) are non-profit organizations that bridge the gap between the need for new treatments for poverty-related diseases and the resources available to develop them, leveraging a mix of public, philanthropic, multilateral, and private sector funding. This paper describes how two financial metrics were used to estimate the return on investments of drugs developed by the PDP Medicines for Malaria Venture (MMV) as a case study.
Methods
The internal rate of return (IRR) and benefit-cost ratio (BCR) were used to estimate the economic return on investment for the PDP. IRR was based on total investments from 2000 to 2023 and health gains derived from PDP-supported drugs, measured as monetized disability-adjusted life years (DALYs) minus the delivery cost of the products. BCR was calculated by dividing the present value of monetized DALYs by the present value of cost, indicating the overall efficiency and impact of the investments received by MMV.
Findings
Total investment received was $2·3 billion over the study period, and the antimalarial drugs developed and launched with the support of MMV averted an estimated 1·6 million deaths and 87 million DALYs for a cost of delivery estimated at $785 million. The IRR for the base scenario was 52·13% (CI: 52·11% - 52·16%) and the BCR 12·99 (CI: 12·92 - 13·06).
Interpretation
The substantial IRR and BCR generated by investment in antimalarial drug development suggest that the PDP model has a potentially pivotal role to play in global health.
Funding
No funding to declare.
